Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$53.20 USD

53.20
3,871,981

+2.00 (3.91%)

Updated Jul 25, 2024 03:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (201 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

EMA Accepts Regeneron/Sanofi's application for Dupixent

Regeneron and partner Sanofi's application for the label expansion of Dupixent has been accepted by the regulatory body in Europe. The application is also under review in the United States.

    3 Sell-Rated Drug Stocks Investors Should Avoid for Now

    Despite a fairly upbeat performance of the pharma and biotech sector, caution has to be exercised before choosing a stock for investment as a few drug companies are struggling to revive business.

      Kinjel Shah headshot

      4 Top-Ranked Drug/Biotech Stocks to Buy as Q1 Nears End

      The first quarter of 2018 is drawing to a close. With the outlook optimistic for the rest of the year, we highlight four drug/biotech stocks worth buying

        Amgen's Repatha Gains CHMP Nod to Include Outcomes Data

        Amgen (AMGN) gets CHMP's positive opinion to incorporate a new indication into the European label of its PCSK9 inhibitor, Repatha.

          Immune Design Poised on Progress of Pipeline Candidates

          Development of key pipeline candidates CMB305 and G100 is likely to keep Immune Design (IMDZ) on a growth trajectory.

            Is Sanofi (SNY) a Great Stock for Value Investors?

            Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.

              The Zacks Analyst Blog Highlights: AT&T, Goldman Sachs, Sanofi, General Mills and Discovery

              The Zacks Analyst Blog Highlights: AT&T, Goldman Sachs, Sanofi, General Mills and Discovery

                Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q4

                Immune Design (IMDZ) reports narrower-than-expected loss in fourth quarter 2017 results and updates data for its pipeline candidates.

                  Sweta Jaiswal headshot

                  Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns

                  Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.

                    Mark Vickery headshot

                    Top Research Report for AT&T, Goldman Sachs & Sanofi

                    Today's Research Daily features new research reports on 16 major stocks, including AT&T (T), Goldman Sachs (GS) and Sanofi (SNY).

                      Biotech Stock Roundup: REGN Cuts Praluent Price, OREX to File for Bankruptcy

                      The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.

                        Kevin Cook headshot

                        Bull of the Day: Regeneron (REGN)

                        Key pharma franchises in a bustling pipeline have shares looking attractive again at 17X and 15% EPS growth

                          3 Biotech Stocks With Rising Earnings Estimates Post Q4

                          The biotech industry performed reasonably well in Q4. Hence, it is a good idea to select stocks from the sector which saw positive estimate revisions post Q4 earnings release.

                            Regeneron and Sanofi Announce Positive Data on Praluent

                            Regeneron (REGN) & Sanofi's Praluent achieves the primary endpoint in the ODYSSEY OUTCOMES trial as the drug reduces the overall risk of MACE by 15%.

                              Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck

                              Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck

                                Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta

                                The biotech sector was in focus last week with these stories - FDA's acceptance of Regeneron's Dupixent's application for asthma, Biogen and partner AbbVie's decision to withdraw multiple sclerosis drug among others.

                                  Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck

                                  Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck

                                    FDA Accepts Regeneron/Sanofi's Dupixent sBLA for Asthma

                                    Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi announced that the FDA has accepted the companies' sBLA for Dupixent for asthma with a target date of Oct 20, 2018.

                                      4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio

                                      Though the large-cap pharma sector struggled a little after a strong start in 2018, it is largely expected to rebound as the year progresses.

                                        Sweta Killa headshot

                                        Biotech Crushing the Market: Best ETFs & Stocks YTD

                                        The recent developments are fueling growth in the biotech companies, leading to a rally in their share prices and impressive levels of momentum in biotech ETFs.

                                          Emergent (EBS) Q4 Earnings Beat Estimates, 2018 View Solid

                                          Emergent's (EBS) earnings and revenues beat estimates in Q4. The top line also improves year over year on higher product sales.

                                            BioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat

                                            BioMarin (BMRN) reports wider-than-expected loss in the fourth quarter of 2017 but beat estimates for sales on higher product revenues.

                                              Merck to Buy Australian Firm to Boost Immunotherapy Pipeline

                                              Merck (MRK) to buy Australian oncolytic immunotherapies maker Viralytics Limited to strengthen its presence in the fast growing immuno-oncology market.

                                                The Zacks Analyst Blog Highlights: ExxonMobil, Caterpillar, Union Pacific, Alexion and Sanofi

                                                The Zacks Analyst Blog Highlights: ExxonMobil, Caterpillar, Union Pacific, Alexion and Sanofi

                                                  Mark Vickery headshot

                                                  Top Research Reports for ExxonMobil, Caterpillar & Union Pacific

                                                  Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil (XOM), Caterpillar (CAT) and Union Pacific (UNP).